![Kaplan-Meier plot of time to first use of a wheelchair by treatment... | Download Scientific Diagram Kaplan-Meier plot of time to first use of a wheelchair by treatment... | Download Scientific Diagram](https://www.researchgate.net/publication/340304404/figure/fig2/AS:875127994593287@1585658181790/Kaplan-Meier-plot-of-time-to-first-use-of-a-wheelchair-by-treatment-group-Fingolimod.png)
Kaplan-Meier plot of time to first use of a wheelchair by treatment... | Download Scientific Diagram
![The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry | BMC Neurology | Full Text The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry | BMC Neurology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12883-023-03273-9/MediaObjects/12883_2023_3273_Fig4_HTML.png)
The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry | BMC Neurology | Full Text
![Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry - Butzkueven - 2022 - European Journal of Neurology - Wiley Online Library Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry - Butzkueven - 2022 - European Journal of Neurology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/619d153f-6fc5-401e-944c-7e697c0a9afa/ene14824-fig-0003-m.jpg)
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry - Butzkueven - 2022 - European Journal of Neurology - Wiley Online Library
![Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry - Butzkueven - 2022 - European Journal of Neurology - Wiley Online Library Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry - Butzkueven - 2022 - European Journal of Neurology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/786fd947-368a-4610-abd5-be8ef2992877/ene14824-fig-0002-m.jpg)
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry - Butzkueven - 2022 - European Journal of Neurology - Wiley Online Library
![The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry | BMC Neurology | Full Text The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry | BMC Neurology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12883-023-03273-9/MediaObjects/12883_2023_3273_Fig3_HTML.png)
The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry | BMC Neurology | Full Text
![JCM | Free Full-Text | Symptom-Level Disability Status Assessed with an Electronic Unsupervised Patient-Reported Expanded Disability Status Scale (ePR-EDSS) in Multiple Sclerosis Patients—The Example of Croatia JCM | Free Full-Text | Symptom-Level Disability Status Assessed with an Electronic Unsupervised Patient-Reported Expanded Disability Status Scale (ePR-EDSS) in Multiple Sclerosis Patients—The Example of Croatia](https://www.mdpi.com/jcm/jcm-11-04081/article_deploy/html/images/jcm-11-04081-g001.png)
JCM | Free Full-Text | Symptom-Level Disability Status Assessed with an Electronic Unsupervised Patient-Reported Expanded Disability Status Scale (ePR-EDSS) in Multiple Sclerosis Patients—The Example of Croatia
![Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/b54493c4-092f-4a47-a243-0647e16716b8/gr2_lrg.jpg)